{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:22:18Z","timestamp":1783786938804,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["R.11012\/04\/2018"],"award-info":[{"award-number":["R.11012\/04\/2018"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ygyno.2021.05.025","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T23:17:38Z","timestamp":1622589458000},"page":"382-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pazopanib based oral metronomic therapy for platinum resistant\/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial"],"prefix":"10.1016","volume":"162","author":[{"given":"Aparna","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayank","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat Singh","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnubhatla","family":"Sreenivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2021.05.025_bb0005","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ygyno.2004.03.023","article-title":"Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials","volume":"93","author":"Markman","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2021.05.025_bb0010","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2021.05.025_bb0015","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2021.05.025_bb0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.05.025_bb0025","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4103\/ijmr.IJMR_2030_18","article-title":"Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: a retrospective analysis","volume":"150","author":"Sharma","year":"2019","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ygyno.2021.05.025_bb0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JGO.19.00331","article-title":"Pazopanib and oral cyclophosphamide in women with platinum-resistant or -refractory epithelial ovarian cancer","volume":"6","author":"Gulia","year":"2020","journal-title":"JCO Glob. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.05.025_bb0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/0008-5472.CAN-06-3282","article-title":"Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer","volume":"67","author":"Kamat","year":"2007","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2021.05.025_bb0040","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ncponc1051","article-title":"Angiogenesis as a strategic target for ovarian cancer therapy","volume":"5","author":"Spannuth","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.05.025_bb0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","article-title":"Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches","volume":"34","author":"Choi","year":"2015","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"10.1016\/j.ygyno.2021.05.025_bb0050","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bjc.1997.537","article-title":"Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels","volume":"76","author":"Yamamoto","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2021.05.025_bb0055","doi-asserted-by":"crossref","first-page":"e0156403","DOI":"10.1371\/journal.pone.0156403","article-title":"The development of an angiogenic protein \u201csignature\u201d in ovarian cancer ascites as a tool for biologic and prognostic profiling","volume":"11","author":"Trachana","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ygyno.2021.05.025_bb0060","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.4161\/cbt.6.12.4976","article-title":"PDGF BB induces VEGF secretion in ovarian cancer","volume":"6","author":"Matei","year":"2007","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.ygyno.2021.05.025_bb0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/IGC.0000000000001171","article-title":"Platelet-derived growth factor D is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer","volume":"28","author":"Zhang","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2021.05.025_bb0070","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/1078-0432.CCR-08-2031","article-title":"Randomized phase II designs","volume":"15","author":"Rubinstein","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2021.05.025_bb0075","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1158\/1078-0432.CCR-09-3287","article-title":"The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee","volume":"16","author":"Seymour","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2021.05.025_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.05.025_bb0085","author":"CTCAE Files"},{"key":"10.1016\/j.ygyno.2021.05.025_bb0090","author":"Questionnaires"},{"key":"10.1016\/j.ygyno.2021.05.025_bb0095","author":"Tumor Markers"},{"issue":"5","key":"10.1016\/j.ygyno.2021.05.025_bb0105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.05.025_bb0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2017.4218","article-title":"Paclitaxel with and without Pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial","volume":"4","author":"Richardson","year":"2018","journal-title":"JAMA Oncol."},{"issue":"30","key":"10.1016\/j.ygyno.2021.05.025_bb0115","first-page":"3374","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J. Clin. Densitom."},{"issue":"6 Suppl 14","key":"10.1016\/j.ygyno.2021.05.025_bb0120","first-page":"25","article-title":"Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this \u201cnew drug\u201d in the management of platinum-refractory disease?","volume":"19","author":"Markman","year":"1992","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.05.025_bb0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/bjc.1994.33","article-title":"Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease","volume":"69","author":"Seymour","year":"1994","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2021.05.025_bb0130","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(18)30349-8","article-title":"Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study","volume":"19","author":"Lan","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.05.025_bb0135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2011.11.035","article-title":"Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a gynecologic oncology group phase II trial","volume":"124","author":"Randall","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.05.025_bb0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2008.01.039","article-title":"Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"109","author":"Ferrandina","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.05.025_bb0145","doi-asserted-by":"crossref","first-page":"515556","DOI":"10.3389\/fimmu.2020.515556","article-title":"Quantification of bevacizumab activity following treatment of patients with ovarian cancer or glioblastoma","volume":"11","author":"Lallemand","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2021.05.025_bb0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.05.025_bb0155","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","author":"Zsiros","year":"2020","journal-title":"JAMA Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821004315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821004315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:56:43Z","timestamp":1758772603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821004315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0090825821004315"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pazopanib based oral metronomic therapy for platinum resistant\/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}